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Abstract The optimal treatment of depressed patients
remains one of the most important challenges concerning
depression. The identification of the best treatment strate-
gies and development of new, safer, and more effective
agents are crucial. The glutamatergic system seems to be a
promising drug target, and consequently the use of the
NMDA receptor ligands, particularly in co-administration
with other substances exerting the antidepressant activity,
has emerged among the new ideas. The objective of this
study was to examine the effect of caffeine on the perfor-
mance of mice treated with various NMDA modulators in
the forced swim test. We demonstrated a significant
interaction between caffeine (5 mg/kg) and the following
NMDA receptor ligands: MK-801 (an antagonist binding in
the ion channel, 0.05 mg/kg), CGP 37849 (an antagonist of
the glutamate site, 0.312 mg/kg), L-701,324 (an antagonist
of the glycine site, 1 mg/kg), and D-cycloserine (a high-
efficacy partial agonist of the glycine site, 2.5 mg/kg),
while the interaction between caffeine and the inorganic
modulators, i.e., Zn2? (2.5 mg/kg) and Mg2? (10 mg/kg),
was not considered as significant. Based on the obtained
results, the simultaneous blockage of the adenosine and
NMDA receptors may be a promising target in the devel-
opment of new antidepressants.
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Introduction
According to World Health Organization (WHO), depres-
sion is one of the five most serious health problems in the
world the prevalence of which continues to increase. It is
estimated that by 2020, major depression will be the sec-
ond most common illness (after cardiovascular disease)
and cause of premature death (Murray and Lopez 1997).
Patients with mood disorders are at increased risk of car-
diac mortality and morbidity (Carney et al. 2002) as well as
at increased risk of suicide attempts (Goldney 2003; Lowe
et al. 2008; Tondo et al. 2003). Although the medical world
realizes that the etiology of depression is complex and it
involves numerous biological, psychological, and social
factors, there are still several unsolved ‘‘mysteries’’ around
this mental disease. Scientific research on epidemiology,
risk factors, and development of depression has been
continuously performed for decades. One of the most
important remaining challenges is the optimal treatment of
depressed patients. The therapeutic efficiency of antide-
pressant medications used in contemporary clinical prac-
tice reaches approximately 70 % (Keller and Boland 1998;
Solomon et al. 2000). Besides, the available drugs evoke a
great number of adverse reactions and it requires at least
2 weeks of administration to observe the first signs of
improvement. Thus, the identification of the best treatment
strategies and the development of new, safer, and more
effective agents are crucial (Skolnick et al. 2009). Scien-
tists focus on both novel chemical compounds with an
antidepressant potential and the unique combinations of
well-known drugs. Mineral substances (such as magnesium
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or zinc) and natural herbal extracts from widely recognized
herbal materials (such as Hyperici herba, Panax ginseng,
Eleutherococcus senticosus, Colae semen) and from less
known ones (like Ilex paraguariensis) are in the limelight,
as well (Nowak 2009).
Since a growing body of evidence indicates that the
glutamatergic system is implicated in the pathogenesis of
depression, antagonism of different sites at the NMDA
receptor complex has emerged among the new treatment
strategies. For example, D-cycloserine, known as a partial
agonist of the NMDA-associated glycine site, acts at the
higher doses (above 100 mg/day) as a functional antagonist
of the NMDA receptor. As a well-tolerated adjuvant
medication, it produces a significant antidepressant effect
in patients refractory to treatment (Heresco-Levy et al.
2013). Similarly, a nonspecific NMDA receptor antagonist,
amantadine, potentiates the effects of conventional
antidepressant therapy in nonresponsive patients (Rogo´ _z
et al. 2007). Traxoprodil, a GluN2B subunit-selective
antagonist, appears to be effective and safe for patients
with treatment-refractory major depressive disorder (Pre-
skorn et al. 2008). Several authors have reported the ben-
eficial effects of ketamine and memantine treatment for
depression; however, the efficacy of these uncompetitive
antagonists of the NMDA receptor complex needs further
clinical confirmation (Berman et al. 2000; Chilukuri et al.
2014; Muhonen et al. 2008; Zarate et al. 2006). The
cationic antagonists, i.e., zinc and magnesium, improve the
symptoms of depression by themselves (Eby et al. 2011;
Nowak et al. 2005), and they enhance the efficacy of the
antidepressant drugs (Poleszak 2007; Poleszak et al. 2005;
Szewczyk et al. 2002).
Despite possessing a significant antidepressant potential,
most of the NMDA receptor inhibitors given at pharma-
cologically active doses induce severe undesirable reac-
tions because of which they cannot be used in the treatment
of patients with mood disorders (Farlow 2004; Tricklebank
et al. 1989; Willetts et al. 1990). Nevertheless, the gluta-
matergic system seems to be a promising drug target and
consequently, the efforts to minimize the toxicity of the
NMDA ligands are undertaken. According to the literature
data, the synergistic antidepressant effect was observed
after concurrent administration of classical antidepressant
drugs, such as fluoxetine, imipramine, citalopram, or
reboxetine and the NMDA receptor blockers, when both
were given at the sub-therapeutic doses (Poleszak et al.
2005, 2011; Szewczyk et al. 2002). Moreover, the out-
comes of our previous experiments revealed that the
combination of two NMDA receptor ligands modulating
the distinct receptor sites induces more pronounced
antidepressant-like effect than monotherapy (Poleszak
et al. 2013).
Caffeine is known as the most widely consumed central-
nervous-system stimulant that predominantly acts through
inhibition of the A1- and A2A-adenosine receptors (Smith
et al. 2006). Surprisingly, caffeine use has been reported to
both increase depressive symptoms (Gilliland and Andress
1981; Greden et al. 1978; James and Crosbie 1987) and
decrease the risk of clinical depression (Hintikka et al.
2005). Some authors claim that the antidepressant effect of
caffeine appears after administration of low doses (Gan
et al. 2009), whereas a long-term use of particularly high
doses of caffeine produces depressive symptoms in humans
(Smith 2002). Interestingly, psychiatric patients have been
reported to consume more caffeine in their diet than the
healthy ones (Scott et al. 1989). Although the exact
molecular mechanism of action has not yet been discov-
ered, it is alleged that caffeine may indirectly impact the
neurotransmissions responsible for the pathomechanism of
the affective disorders (i.e., noradrenergic, serotoninergic,
dopaminergic, and glutamatergic systems) (Smith et al.
2006). In fact, both clinical and preclinical studies have
indicated a link between depression-like behavior and the
adenosine modulatory system, since the adenosine recep-
tors A1 and A2A control the release of serotonin, corti-
cotrophin-cortisol/corticosterone, and glutamate and
influence the hypothalamic–pituitary–adrenal axis to some
extent (Fredholm et al. 2005). Similarly, the available data
regarding adenosine activity are not consistent. Several
reports have demonstrated that adenosine and its analogs
induce behavioral despair in animal models (El Yacoubi
et al. 2003), whereas other authors (Kaster et al. 2004,
2005a, b, 2007, 2012) have shown an antidepressant-like
effect in mice in the forced swim test (FST) after acute
administration of this neuromodulator. According to Kaster
et al. (2004, 2005a, b, 2007, 2012), the observed results
depended most probably on the interaction between A1,
A2A, and 5-HT1A receptors, L-arginine-nitric oxide path-
way, K? channels as well as on the inhibition of the
NMDA receptors.
Since caffeine is a widely consumed psychoactive sub-
stance, it seems highly important to evaluate its potential
for drug interactions with the existing and investigational
treatments. The aim of our study was to assess the influence
of caffeine on the performance of mice treated with various
NMDA modulators in the FST.
Materials and methods
Animals
All experiments were performed with the use of naı¨ve adult
male Albino Swiss mice weighing approximately 25–30 g
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(10–12 weeks old), purchased from a licensed breeder
(Kołacz, Warszawa, Poland). The animals were housed and
tested in accordance with European Union and Polish
legislative acts concerning animal experimentation. Each
mouse was tested only once. The behavioral tests started
after at least a 1-week period of animals’ acclimation to the
laboratory environment. The mice were kept in groups of
10 in standard Makrolon cages (425 mm 9 265 mm 9
150 mm) on wood shavings under controlled housing
conditions (ambient temperature 20–23 C, relative
humidity 45–55 %, 12/12 h light/dark cycle, light on at
6:00 a.m., chow pellets, and tap water continuously avail-
able). The experiments were conducted between 8 a.m. and
3 p.m. to minimize circadian influences. The experimental
groups consisted of 7–10 animals, randomly assigned.
Separate groups of mice were taken for the FST and the
spontaneous locomotor activity studies. The Local Ethics
Committee at the Medical University of Lublin approved
all experimental procedures while all efforts were made to
minimize animal suffering and reduce the number of mice
used in the experiments.
Drugs
The following substances were used: caffeine (1,3,7-
trimethylxanthine, Sigma-Aldrich, Poznan´, Poland), imipra-
mine (30 mg/kg, Polfa, Krako´w, Poland), MK-801 (di-
zocilpine, (5R,10S)-(?)-5-methyl-10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate,
0.05 mg/kg, Sigma-Aldrich), CGP 37849 (dl-(E)-amino-4-
methyl-5-phosphono-3-pentenoic acid, 0.3 mg/kg, Abcam
Biochemicals, Cambridge, UK), L-701,324 (7-chloro-4-hy-
droxy-3-(3-phenoxy)phenylquinolin-2[1H]-one, 1 mg/kg,
Sigma-Aldrich), D-cycloserine (d-4-amino-3-isoxazolidone,
2.5 mg/kg, Sigma-Aldrich), magnesium hydroaspartate
(Farmapol, Poznan´, Poland), and zinc hydroaspartate (Farm-
apol). Both the active dose of imipramine and the ineffective
doses of the NMDA receptor ligands were selected on the
basis of the outcomes of our previous experiments (Poleszak
et al. 2005, 2013). Doses of magnesium and zinc refer to pure
magnesium and zinc ions—10 and 2.5 mg/kg, respectively.
Caffeine, imipramine, MK-801, CGP 37849, D-cycloserine,
and the salts of divalent cations were dissolved in physiolog-
ical saline, while L-701,324 was suspended in a 1 % aqueous
solution of Tween 80 (POCH, Gliwice, Poland). All the
solutions and the suspension were prepared immediately prior
to the experiments and they were given intraperitoneally (i.p.).
All agents except for caffeine and magnesium hydroaspartate
were injected 60 min before behavioral testing, while caffeine
and magnesium hydroaspartate were administered 40 and
30 min prior to the experiments, respectively. The control
groups received saline. The volume of vehicle or drug solu-
tions/suspension for i.p. administration was 10 ml/kg.
Forced swim test
The forced swim test was conducted as described in the
literature (Porsolt et al. 1977). Each animal was placed in a
glass cylinder (height 25 cm, diameter 10 cm) containing
10 cm of water at the temperature of 23–25 C and left for
6 min. As little immobility was observed during the first
2 min, the total duration of immobility was recorded
between the 2nd and the 6th minute of the experiment. The
animal was judged to be immobile when it stopped strug-
gling and was making only the movements necessary to
keep its head above the water level.
Spontaneous locomotor activity
The determination of the spontaneous locomotor activity of
animals is a complementary procedure which is performed
to confirm that the interpretation of the outcomes obtained
in the FST is not disturbed by changes in the animals’
locomotion. In our experiments, the spontaneous locomotor
activity was measured with Opto-Varimex-4 Auto-Track
(Columbus Instruments, Columbus, OH, USA)—an auto-
matic device with four transparent cages covered with
movable lids, a set of four infrared emitters (with laser
beams), and four detectors monitoring animal movements.
Each mouse was placed in an individual cage and left there
for 6 min. The spontaneous locomotor activity was eval-
uated between the 2nd and the 6th minute, which corre-
sponds with the time interval analyzed in the FST. It was
measured as a distance (in cm) traveled by a mouse.
Statistical analysis
The obtained data were assessed by the one-way analysis
of variance (ANOVA) followed by Dunnett’s post hoc test
or by the two-way analysis of variance (ANOVA) followed
by Bonferroni’s post hoc test, depending on the experi-
mental design. All results are presented as the mean ± s-
tandard error of the mean (SEM). p was considered as
statistically significant when *p\ 0.05, **p\ 0.01,
***p\ 0.001. Statistical analysis was performed with
GraphPad Prism version 5.03 for Windows (GraphPad
Software, San Diego, CA, USA).
Results
Effect of an acute administration of caffeine
on the FST in mice
As shown in Fig. 1, caffeine after i.p. administration exerted
an antidepressant-like effect in the FST in mice. The
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antidepressant potential was significant within the dose
range of 10–50 mg/kg. One-way ANOVA revealed the
following statistics: F(5,48) = 8.900, p\ 0.0001. The
concentration of 5 mg/kg appeared to be a sub-effective
dose. Imipramine, used as a positive control at a dose of
30 mg/kg, also considerably reduced the immobility time of
mice left in the inescapable situation, which confirmed the
correctness of the applied methodology. The tested doses of
caffeine did not influence the locomotion of mice (Table 1).
Effect of a joint administration of caffeine and MK-
801 on the FST in mice
The concurrent acute i.p. administration of caffeine (5 mg/
kg) and MK-801 (0.05 mg/kg) induced an antidepressant-
like effect in the FST in mice, which is illustrated in
Fig. 2a. Two-way ANOVA revealed a significant caffeine–
MK-801 treatment interaction with significant effects of
both used agents. The post hoc analysis showed that co-
administration of caffeine and MK-801 significantly
(p\ 0.001) shortened the total duration of immobility in
mice, as compared to both the single-treated and vehicle-
treated animals. Statistical analysis of the results obtained
from the spontaneous locomotor activity indicated not
significant caffeine–MK-801 treatment interaction with not
quite significant effect of caffeine and significant effect of
MK-801. Although neither caffeine nor MK-801 given
separately as a single dose influenced the distance traveled
by mice, the combination therapy increased the locomotor
activity of animals in comparison to both saline- and caf-
feine-treated groups. The outcomes obtained in the spon-
taneous locomotor activity test are summarized in Fig. 3a.
Effect of a joint administration of caffeine and CGP
37849 on the FST in mice
Caffeine and CGP 37849 administered at the doses of 5 and
0.3 mg/kg, respectively, did not induce a significant
reduction in the immobility time of animals, but their co-
administration shortened the total duration of immobility
compared to caffeine and saline (p\ 0.001) but not to
CGP 37849 (p[ 0.05). Accordingly, two-way ANOVA
demonstrated that the caffeine–CGP 37849 treatment
interaction was considered significant with a significant
effect of caffeine and non-significant effect of CGP 37849
(Fig. 2b). The tested treatment combination did not affect
the outcomes of the spontaneous locomotor activity
(Fig. 3b). Two-way ANOVA demonstrated not significant
effect of caffeine–CGP 37849 treatment interaction with
significant effect of caffeine and not significant effect of
CGP 37849.
Effect of a joint administration of caffeine and L-
701,324 on the FST in mice
Two-way ANOVA indicated a significant caffeine treat-
ment 9 L-701,324 treatment interaction with significant
effects of both caffeine (5 mg/kg) and L-701,324 (1 mg/
kg). According to the post hoc analysis, the concomitant
injection of per se inactive doses of caffeine and L-701,324
resulted in a considerable (p\ 0.001) shortening of the
total duration of immobility in mice compared with either
drug alone as well as the vehicle-treated group (Fig. 2c).
No modification in the animals’ spontaneous locomotor
activity was recorded between the 2nd and the 6th minute
of the experiment (Fig. 3c). Two-way ANOVA revealed
not significant caffeine treatment 9 L-701,324 treatment
interaction with significant effect of caffeine and not sig-
nificant effect of L-701,324.
Fig. 1 Effect of an acute administration of different caffeine doses on
immobility time in the FST in mice. Caffeine (5, 10, 20, or 50 mg/kg)
and imipramine (IMI, 30 mg/kg) were administered i.p. 40 and
60 min before the experiment, respectively. The acute administration
of imipramine was used as a positive control. The values represent the
mean ? SEM (n = 8–10 mice per group). *p\ 0.05, ***p\ 0.001
versus saline-treated group (one-way ANOVA followed by Dunnett’s
post hoc test)
Table 1 Effect of an acute administration of caffeine on the spon-
taneous locomotor activity in mice
Treatment Dose (mg/kg) Activity counts between
the 2nd and the 6th minute
(cm)
Saline – 956.4 ± 68.87
Caffeine 5 1057 ± 54.20
Caffeine 10 1145 ± 139.8
Caffeine 20 1143 ± 132.1
Caffeine 50 1107 ± 84.90
Data represent the mean ± SEM (n = 8 mice per group). Caffeine
was administered i.p. 40 min before the test at the following doses: 5,
10, 20, or 50 mg/kg. The difference was considered statistically sig-
nificant if p\ 0.05 (one-way ANOVA [F(4,35) = 0.5921,
p = 0.670])
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Fig. 2 Effect of a joint administration of caffeine (5 mg/kg) and the
NMDA receptor ligands: a MK-801 (0.05 mg/kg), b CGP 37849
(0.3 mg/kg), c L-701,324 (1 mg/kg), d D-cycloserine (DCS, 2.5 mg/
kg), e magnesium hydroaspartate (10 mg/kg, Mg), and f zinc
hydroaspartate (2.5 mg/kg, Zn) in the FST in mice. MK-801, CGP
37849, L-701,324, DCS and Zn were given 60 min before the
experiment while caffeine and Mg were injected 40 and 30 min
before the test, respectively. All agents were administered i.p. The
control groups received saline. The values represent the mean ? -
SEM (n = 9–10 mice per group). Two-way ANOVA for caffeine–
treatment interactions: a F(1,35) = 9.55, p = 0.0039;
b F(1,36) = 4.29, p = 0.0455; c F(1,36) = 14.38, p = 0.0005;
d F(1,36) = 42.04, p\ 0.0001; e F(1,36) = 0.08, p = 0.7823;
f F(1,36) = 0.00, p = 0.9852; ***p\ 0.001 (Bonferroni’s post hoc
test)
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Effect of a joint administration of caffeine and D-
cycloserine on the FST in mice
Two-way ANOVA revealed a significant caffeine treat-
ment 9 D-cycloserine treatment interaction with significant
effects of both caffeine (5 mg/kg) and D-cycloserine
(2.5 mg/kg). Relying on the post hoc outcomes, the
combination of caffeine and D-cycloserine markedly
reduced the immobility time of the animals, as compared to
both single-treated groups (p\ 0.001) and saline-treated
mice (p\ 0.001) (Fig. 2d). No significant difference was
found in relation to the animals’ locomotion after admin-
istration of the tested substances (Fig. 3d). According to
two-way ANOVA, caffeine–D-cycloserine treatment
Fig. 3 Effect of a joint administration of caffeine (5 mg/kg) and the
NMDA receptor ligands: a MK-801 (0.05 mg/kg), b CGP 37849
(0.3 mg/kg), c L-701,324 (1 mg/kg), d D-cycloserine (DCS, 2.5 mg/
kg), e magnesium hydroaspartate (10 mg/kg, Mg) and f, zinc
hydroaspartate (2.5 mg/kg, Zn) on the spontaneous locomotor activity
in mice. MK-801, CGP 37849, L-701,324, DCS, and Zn were given
60 min before the experiment while caffeine and Mg were injected 40
and 30 min before the test, respectively. All agents were administered
i.p. The control groups received saline. The values represent the
mean ? SEM (n = 7–8 mice per group). Two-way ANOVA for
caffeine–treatment interactions: a F(1,27) = 0.89, p = 0.3535;
b F(1,27) = 0.45, p = 0.5074; c F(1,26) = 0.62, p = 0.4369;
d F(1,26) = 0.30, p = 0.5891; e F(1,27) = 0.44, p = 0.5136;
f F(1,26) = 3.96, p = 0.0572
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interaction was considered not significant with significant
effect of caffeine and not significant effect of D-
cycloserine.
Effect of a joint administration of caffeine
and magnesium hydroaspartate on the FST in mice
As seen in Fig. 2e, the joint administration of sub-effective
doses of caffeine (5 mg/kg) and magnesium hydroaspartate
(10 mg/kg) produced no antidepressant-like effect in the
FST in mice. A non-significant caffeine treat-
ment 9 magnesium hydroaspartate treatment interaction
with a non-significant effect of magnesium hydroaspartate
but a significant effect of caffeine were demonstrated by
two-way ANOVA. Similarly, the administration of the
tested agents did not alter the distance traveled by the
animals (Fig. 3e). Two-way ANOVA showed not signifi-
cant caffeine–magnesium hydroaspartate treatment inter-
action with no effect of either tested substance.
Effect of a joint administration of caffeine and zinc
hydroaspartate on the FST in mice
Caffeine (5 mg/kg) and zinc hydroaspartate (2.5 mg/kg)
when given together did not exert any influence on the
animals’ performance in the FST (Fig. 2f). Statistical
analysis showed a non-significant caffeine treat-
ment 9 zinc hydroaspartate treatment interaction with a
non-significant effect of caffeine but a significant effect of
zinc hydroaspartate. The outcomes of the spontaneous
locomotor activity studies indicated not quite significant
caffeine–zinc hydroaspartate treatment interaction with not
significant effect of caffeine and significant effect of zinc
hydroaspartate. However, both single injection of zinc
hydroaspartate as well as its combination with caffeine
considerably attenuated mice locomotion as compared to
the saline-treated as well as saline-treated and caffeine-
treated group, respectively. The results are presented in
Fig. 3f.
Discussion
The primary effects of caffeine include stimulation of the
central-nervous system with reduction of fatigue,
enhancement of mental performance, increase of alertness,
and mood elevation (Winston et al. 2005). Although the
pharmacological activity of caffeine is mediated via
antagonism of the A1 and A2 receptors, caffeine at higher
doses also inhibits phosphodiesterases, blocks the GABAA
receptor, and causes the mobilization of intracellular cal-
cium (Daly and Fredholm 1998). Blockage of the adeno-
sine receptor is known to reverse the inhibition of
adrenaline release which leads to sympathetic stimulation.
Moreover, through the antagonism of the A2A receptors,
caffeine indirectly influences the dopamine receptors. As
was underlined by Ferre et al. (1992), an intact dopamin-
ergic neurotransmission is required for the stimulatory
effects of caffeine.
In the present study, we found that caffeine at a dose of
50 mg/kg reduced the immobility time in the FST to almost
the same degree as an effective dose of imipramine, used as
a positive control. In line with Kale and Addepalli (2014), a
dose of 10 mg/kg (and 20 mg/kg) exerted the antidepres-
sant-like activity, as well. Our observations confirm the
reports on the relationship between caffeine consumption
and the improved mood or reduction in depressive-like
symptoms (Amendola and van Steensel 2014; Childs and
de Wit 2008). Other adenosine A2A receptor antagonists
(e.g., SCH58261, ZM241385, KW6002) also reversed the
signs of behavioral despair in the FST and the tail sus-
pension test (TST) (El Yacoubi et al. 2003). Although
several authors have reported that caffeine may increase
the rodents’ locomotion in an inverted U-shaped manner
(Finn and Holtzman 1987), none of the doses tested in our
experiments influenced the locomotor activity of animals.
Therefore, the recorded antidepressant-like effect of this
methylxanthine was not due to its psychostimulant action.
The same conclusions have been drawn by Pechlivanova
et al. (2009). It is worth mentioning that the daily mean
intake of caffeine reaches 1–2 mg/kg (i.e., 70–140 mg in a
70 kg individual), and this index seems to vary between
countries and age groups. For example, for the Scandina-
vians, it even increases to 7 mg/kg/day which corresponds
to about seven cups of coffee (Nehlig et al. 1992). How-
ever, one should remember that results from experiments
based on the rodent models should not be directly extrap-
olated and applied to human conditions.
The non-effective dose of caffeine (5 mg/kg) given
concurrently with also inactive doses of the NMDA
receptor antagonists (i.e., MK-801, CGP 37849,
L-701,324) or a partial agonist of a glycine recognition site
(D-cycloserine) significantly reduced the immobility time
of animals in the FST, suggesting a synergistic interaction
between the tested agents. As for CGP 37849, L-701,324,
and D-cycloserine, the observed outcomes were not influ-
enced by the change in the overall spontaneous locomotor
activity of the tested animals, since their respective com-
binations with caffeine did not increase the distance trav-
eled by mice as compared with the control groups. Mice
given MK-801 in combination with caffeine traveled a
considerably longer distance than animals from the control
groups, although neither MK-801 nor caffeine increased
the animals’ locomotion by themselves. According to the
literature data, MK-801 produces the motor-activating
effects, though only after doses higher than the ones used in
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the present study (Dall’Igna et al. 2003). Similar to our
results, co-administration of caffeine and ketamine (an-
other antagonist of the NMDA receptor complex) signifi-
cantly enhanced the ambulatory activity of mice
(Uchihashi et al. 1992). Most probably, dopamine release
was involved in the observed effects. Moreover, system-
atically administered caffeine potentiated the locomotor
stimulation produced by MK-801 in mice (Kuribara et al.
1992). A pharmacological interaction between caffeine and
MK-801 concerning the locomotor effect was also descri-
bed by de Oliveira et al. (2005) and Dall’Igna et al. (2003).
Subchronic and chronic exposure to caffeine resulted in the
development of tolerance to MK-801-induced hyperloco-
motion in mice. Contribution of the dopaminergic system
to the increase of locomotor activity observed in our study
after concomitant administration of caffeine and MK-801
cannot be ruled out. There are findings suggesting impli-
cation of the dopamine system in the locomotor stimulant
effects of caffeine per se, whereas other studies indicate
that caffeine enhances the locomotor activity effects pro-
duced by dopamine receptor agonists acting directly and
indirectly (Garrett and Griffiths 1997). Fraser et al. (1997)
revealed that the endogenous adenosine activity through
the A1 receptors may be responsible, at least partially, for
the locomotor stimulant properties of MK-801 recorded in
the elevated plus maze test, while the motor-activating
effects of acutely administered caffeine could have been
mediated by a simultaneous blockage of the central ade-
nosine A1 and A2A receptors (Karcz-Kubicha et al. 2003).
The synergistic interaction between adenosine and glu-
tamatergic systems detected in our study is not highly
surprising, since such an interplay has been described in the
literature (de Oliveira et al. 2005). Activation of the
NMDA receptor induces adenosine release in the rat
striatum and cortex (Craig and White 1993; Melani et al.
1999), while activation of the adenosine receptors reduces
NMDA receptor-mediated effects (Sebastia˜o and Ribeiro
2000). Theophylline (an antagonist of the adenosine
receptor) given to haloperidol-treated animals enhanced the
anticataleptic effects of NMDA receptor antagonists
(Hauber and Munkle 1996). Moreover, NMDA receptor
blockage counteracted the acute behavioral effects of caf-
feine withdrawal (Sukhotina et al. 2004), while adenosine
receptor agonists counteracted the behavioral and neuro-
physiological changes caused by NMDA receptor antago-
nists in the animal models (Browne and Welch 1982;
Popoli et al. 1997). Bespalov et al. (2006) demonstrated a
synergistic interaction between NMDA receptor antago-
nists and caffeine. The observed effect was limited to the
low dose of caffeine (i.e., 3 mg/kg), which was comparable
to the one tested in our study. Such low caffeine doses act
selectively through the adenosine receptors and produce
stimulatory effects (Fredholm et al. 1999).
According to de Oliveira et al. (2005), an abrupt reduction
of adenosine release may contribute to the locomotor and
cognitive effects observed after NMDA receptor inhibition. It
could explain the synergistic interaction between NMDA
receptor antagonists and caffeine that was demonstrated in
our study. However, the relationship between adenosinergic
and glutamatergic systems is quite complicated, since co-
administration of the sub-effective doses of adenosine with
MK-801, ketamine, and zinc chloride also resulted in a syn-
ergistic effect in the FST, while administration of an active
dose of A1 agonist (i.e., N
6-cyclohexyladenosine) or adeno-
sine prevented the binding of MK-801 to the NMDA recep-
tor. Moreover, N-methyl-D-aspartate (NMDA receptor
agonist) and D-serine (an endogenous agonist of the glycine
site) prevented the anti-immobility effect induced by adeno-
sine in the FST (Kaster et al. 2012). According to Kaster et al.
(2012), the inhibition of the NMDA receptor mediated by the
activation of the A1 receptors may underlie the antidepres-
sant-like activity of adenosine.
Activation of adenosine A1 and A2A receptors is also
partially responsible for the antidepressant-like potential of
zinc ions (Lobato et al. 2008), which could be an explana-
tion for the lack of a synergistic interaction between caffeine
and zinc hydroaspartate in the FST in the present study. Our
observations are in accordance with the reports of Lobato
et al. (2008), who showed that the anti-immobility effect of
zinc chloride was reversed by pretreatment with the non-
selective and selective antagonists of adenosine receptors
(i.e., caffeine, DPCPX or ZM241385), given at sub-effective
doses. On the other hand, both selective agonists of adeno-
sine receptor (CHA, DPMA) and an adenosine transporter
inhibitor (dipyridamole) enhanced the antidepressant-like
effect of an inactive dose of zinc ions. Similar research
should be performed in order to check if the same mecha-
nisms are responsible for the lack of a synergistic interaction
between caffeine and magnesium hydroaspartate.
It should be underlined that in view of several limita-
tions of our study (small sample size, only one test per-
formed, only one time point analyzed, no molecular
analysis), the obtained results should be treated as the
preliminary ones that need to be confirmed.
Conclusion
The antidepressant-like potential of the NMDA receptor
antagonists with the affinity to distinct binding sites (except
for zinc and magnesium ions) was significantly augmented
by the concomitant administration of caffeine. Therefore,
the simultaneous blockage of the adenosine and NMDA
receptors may offer an alternative target in the develop-
ment of new pharmacological options for the treatment of
depression.
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